Skip to main content

$0.625 0.005 (0.81%)

High

$0.63

Low

$0.59

Trades

32

Turnover

$33,720

Volume

55,179
30 June 2023 at 4:10pm
Register to track RCE and receive email alerts.
Subject
RCE Ann: Application for quotation of securities - RCE

RCE Ann: Phase I Clinical Trial of R327 I.V. - 6000mg Complete

RCE Ann: Quarterly Activities/Appendix 4C Cash Flow Report

RCE Ann: Corporate Presentation - Aussie Equities Day 2022

RCE Ann: Dr Philip Sutton - V.P. of Translational Sciences

RCE Ann: Phase I Positive Safety Data - 4000mg Complete

RCE Ann: Cleansing Statement

RCE Ann: Application for quotation of securities - RCE

RCE Ann: Conversion of Performance Shares

RCE Ann: Cleansing Statement

RCE Ann: Application for quotation of securities - RCE

RCE Ann: Phase I Clinical Trial R327 Advances to 4000mg

RCE Ann: MDC: Biotech Investors Luncheon Presentations

RCE Ann: Corporate Presentation - Biotech Investor Lunch

RCE Ann: GTG: Biotech Investors Presentation

RCE Ann: Quarterly Activities/Appendix 4C Cash Flow Report

RCE Ann: Cleansing Statement

RCE Ann: Application for quotation of securities - RCE

RCE Ann: Phase I Clinical Trial R327 Advances to High Dose Cohort

RCE Ann: Anti-Viral Patent Granted in Hong Kong

RCE Ann: Cleansing Statement

RCE Ann: Application for quotation of securities - RCE

RCE Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial

RCE Ann: $3.08m R&D Rebate Received

RCE Ann: Safety Committee Clears PhI R327 Dose Increase

RCE Ann: S&P DJI Announces March 2022 Quarterly Rebalance

RCE Ann: Appendix 4D and Interim Financial Report

RCE Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial

RCE Ann: Cleansing Statement

RCE Ann: Notification regarding unquoted securities - RCE

RCE Ann: Application for quotation of securities - RCE

RCE Ann: Positive Safety Data from Third Cohort of PI Clinical Trial

RCE Ann: Quarterly Activities/Appendix 4C Cash Flow Report

RCE Ann: Positive Safety Data from Second Cohort of PI Clinical Trial

RCE Ann: Positive Safety Data from Phase 1 Clinical Trial

RCE Ann: Patients to be Dosed in Ph 1 IV Clinical Trial of R327

RCE Ann: Update on Phase I/II Clinical Trial for Burn Wound Infection

RCE Ann: Results of Meeting

RCE Ann: AGM Presentation

RCE Ann: Opening R&D Address at World AMR Congress

RCE Ann: Appendix 4C and Activity Report

RCE Ann: Ethics Approval to Start Phase 1 Intravenous Clinical Trial

RCE Ann: Letter to Shareholders - Annual General Meeting

RCE Ann: Notice of General Meeting/Proxy Form

RCE Ann: Reinstatement to Official Quotation

RCE Ann: Court Orders Granted

RCE Ann: Suspension from Official Quotation

RCE Ann: Application for quotation of securities - RCE

RCE Ann: Court application and delayed cleansing notice

RCE Ann: Trading halt

Register to track RCE and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
SPL